Open an account

Kodiak Sciences

KOD · NASDAQ

$92.97+$1.62 (+1.77%)TodayMarket closed ·
Prev close $91.35

About KOD

The company is headquartered in Palo Alto, California and currently employs 124 full-time employees. The company went IPO on 2018-10-04.

Employees
124
Headquarters
Palo Alto, California
Listed
Oct 4, 2018
Sector
Health Care
Industry
Biotechnology
Website
kodiak.com

KOD key statistics

Market cap
5.84B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.09M
Volume
868.35K
Open price
$90.84
High today
$96.12
Low today
$89.53
52 Week high
$104.00
52 Week low
$15.83

Kodiak Sciences (KOD) at a glance

As of Oct 20, 2026, Kodiak Sciences (KOD) shares are priced at $92.97, giving the company a market cap of 5.84B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $89.53 and $96.12. The current price is 3.8% above the day's low and 3.3% below its high.

Volume so far is 868.35K shares, below the average of 2.09M shares a day.

Over the past year Kodiak Sciences has ranged from $15.83 to $104.00, and now sits 87% of the way up that range.

Kodiak Sciences met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$1.05 per share against an estimate of -$0.9656.

The average analyst price target is $117.50, 26.4% above the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

83%of 6 analyst ratings say Buy
  • Buy83.3%
  • Hold16.7%
  • Sell0.0%
Price target · 7 analystsAvg $117.50
Low
$96.96
Now
$92.97
High
$152.25

KOD earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 5.7% on average.

  1. Q3 FY24: reported -$0.84 per share against an estimate of -$0.9129
  2. Q4 FY24: reported -$0.84 per share against an estimate of -$0.8933
  3. Q1 FY25: reported -$1.09 per share against an estimate of -$0.9029
  4. Q2 FY25: reported -$1.03 per share against an estimate of -$1.08
  5. Q3 FY25: reported -$1.16 per share against an estimate of -$1.04
  6. Q4 FY25: reported -$1.04 per share against an estimate of -$1.06
  7. Q1 FY26: reported -$0.94 per share against an estimate of -$1.02
  8. Q2 FY26: reported -$1.05 per share against an estimate of -$0.9656

KOD news

  • Press releasePRNewswire

    Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026

  • Shivdeep Dhaliwal

    MongoDB, Kodiak Sciences, Navitas Semiconductor, Boeing and Nvidia: Why These 5 Stocks Are on Investors' Radars Today

  • Avi Kapoor

    Gold Tumbles Over 3%; MongoDB Shares Move Lower

  • Avi Kapoor

    Dow Dips Over 200 Points; Dallas Fed’s Manufacturing Index Declines In September

  • Press releaseGlobe Newswire

    4 Explosive Stories Enter the Investor Spotlight

  • Vandana Singh

    Regeneron Eylea Feels the Pinch as Kodiak Advances Extended Dosing for Eye Drug

  • Vandana Singh

    Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine

  • Press releasePRNewswire

    Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-week Dosing Interval Using Strict Treat-to-Dryness Real World Retreatment Criteria.

Similar companies

Companies in the same industry as Kodiak Sciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.